饒坤銘 主治醫師
1.長庚大學臨床醫學研究所碩士畢業
2.中山醫科大學畢業
3.美國MD ANDERSON CANCER CENTER腫瘤細胞分子生物學研究所
1.高雄長庚醫院內科部 住院醫師
2.高雄長庚血液腫瘤科 住院總醫師
3.高雄長庚血液腫瘤科 主治醫師
4.高雄長庚血液腫瘤科 科主任
血液腫瘤科主治醫師
1.癌症基礎醫學研究
2.癌症診斷與治療
1.內科專科醫師
2.中華民國腫瘤內科專科醫師
3.乳癌醫學會會員
4.乳癌專科醫師
5.中華民國癌症醫學會理事
6.台灣乳房醫學會理事
7.台灣癌症安寧緩和醫學會監事
8.教育部部定助理教授
 
1.Rau KM, Chang CK, Lee KF, Liaw CC*. Changgeng Yi Xue Za Zhi.Successful surgical treatment of solitary adrenal metastases from non-small cell lung cancer: case report. Chang Gung Med J. 1999 Jun;22(2):282-6.

2.Dun-Hia Yan, Kun-ming Rau, Ming-Chi Hong*. Antimetastasis. Cancer Gene Therapy. 2004;19:287-298 (SCI;IF=3.126;Oncology 63/166)

3.Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC*.Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther. 2004 Nov;11(11):740-7. (SCI;IF=3.126;Oncology 63/166)

4.Chen JS*, Huang JS, Yang TS, Lin YC, Wang HM, Liau CT, Rau KM. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Anticancer Drugs. 2005 Jan;16(1):47-51 (SCI;IF=2.230;Pharmacology & Pharmacy 123/237)

5.Rau KM, Kang HY, Cha TL, Miller SA, Hung MC*.The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer. 2005 Sep;12(3):511-32. (SCI;IF=3.126;Oncology 63/166)

6.Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, Liu JS, Huang CH*.Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients.Clin Neurol Neurosurg. 2006 Feb;108(2):150-6. (SCI;IF=1.303;Surgery 83/167)

7.Rau KM, Day CP, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MC*.Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther. 2006 Jul;13(7):706-19. Epub 2006 Mar (SCI;IF=3.126;Oncology 63/166)

8.Huang TL, Huang CH*, Tang Y, Rau KM, Chen YY. Extrapulmonary small cell carcinoma--a medical center` experience. Chang Gung Med J. 2006 Nov-Dec;29(6):590-5

9.Fang FM, Li CF, Chien CY, Rau KM, Huang HY*. Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes. Int J Pediatr Otorhinolaryngol. 2007 Mar;71(3):447-55. (SCI;IF=1.148;Otorhinolaryngology 19/36)

10.Shau-hsuan Li, Sheng-Lan Wang, Wan-Ting Huang, Yi-Cyun Ciou, Kun-ming Rau*.Upper gastrointestinal bleeding as the initial manifestation of lung adenocarcinoma metastatic to the stomach. Respiratory MD/Edicine extra. 2007;3:67-70.

11.Kun-ming Rau*. Hormone therapy for breast cancer. Journal of Cancer Research and Practice,2008 Jun;24:127-131.

12.Chen JS*, Rau KM, Chen YY, Huang JS, Yang TS, Lin YC, Liau CT, Lee KD, Su YC, Kao RH. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2009 Apr;63(5):819-25. (SCI;IF=2.654;Pharmacology & Pharmacy 96/237)

13.Tang ST*, Huang EW, Liu TW, Rau KM, Hung YN, Wu SC.Propensity for Home Death Among Taiwanese Cancer Decedents in 2001-2006, Determined by Services Received at End of Life. J Pain Symptom Manage. 2010 Oct;40:556-574 (SCI;IF=2.423;Medicine, General& Internal 28/133)

14.Rau KM, Lin JN, Lin VC, Shieh PC, Kuo DH, Shieh JC, Chen WJ, Tsai SC, Way TD*.
Resveratrol Modulates Tumor Cell Proliferation and Protein Translation via SIRT1-Dependent AMPK Activation. J Agric Food Chem. 2010 Feb;58:1584-1592. (SCI;IF=2.469;Agriculture, Multidiscipinary 2/45)

15.Wu SC*, Chou FF, Rau KM.Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Aug 19. (SCI;IF=4.859;Oncology 17/141)

16.Su YL, Liu CT, Chiu TJ, Li SH, Huang TL, Chen YY, Tang Y, Rau KM, Huang CH*. Metastatic mucinous colorectal cancer : An important subtype of colorectal cancer with poor response to chemotherapy and overall survival. Journal of Cancer Research and Practice. 2010;26:221-230.

17.Yen-Yang Chen, Chun-Nan Yeh*, Chi-Tung Cheng, Tsung-Wen Chen, Rau KM, Yi-Yin Jan,Miin-Fu Chen.Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World journal of gastroenterology.2011;17:2113-2119. (SCI; IF=1.897; Gastroenterology & hepatology 35/71)

18.Loke SS*, Rau KM . Differences between inpatient hospice care and in-hospital nonhospice care for cancer patients. Cancer Nurs. 2011 May-Jun;34(3):E21-6. (SCI; IF=1.792, Nursing 4/99)

19.Loke SS*, Rau KM, Huang CF. Impact of combined hospice care on terminal cancer patients. Journal of palliative medicine. 2011;14:683-687. (SCI; IF=1.849, Health care sciences & services 30/69)

20.Chou PL*, Rau KM, Lin CC. Development and psychometric testing of a short version of the barriers questionnaire-Taiwan form cancer patients. International journal of nursing studies. 2011;48:1071-1079. (SCI; IF=2.178, Nursing 3/72).

21.Chen YJ, Rau KM, Chien CY, Fang FM, Huang TL, Chiu TJ*. High P16 expression predicts a positive response to chemoradiotherapy in stage IV A/B head and neck squamous cell carcinoma. Asian pacific journal of cancer prevention. 2011;12:649-655. (SCI; IF=0.659, Oncology 147/184)

22.Wu chi ache, Tai-jan chiu, Meng-Chih Lin, Jui-Ling Wang, Kun ming Rau, Chen YY , Huang CH*.Pemetrexed as third-line chemotherapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) : Journal of Cancer Research and Practice.2011;27:157-164.

23.Chen YH, Lu HI, Huang CH, Rau KM, Chiu YC, Wang YM, Chen YY, Liu CT, Li SH*.The use of trimodality treatment of locally advanced resectable esophageal squamous cell carcinoma: a single institute experience in southern Taiwan. Journal of Cancer Research and Practice. 2011; Oct 27(5): 200-210.

24.Rau KM, Li SH, Chen SM, Tang Y, Huang CH, Wu SC, Chen YY*. Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients. Jpn J Clin Oncol. 2011 Apr;41(4):455-61. (SCI; IF=1.783; Oncology 122/166)

25.Rau KM, Chen YJ, Sun MT, Kang HY. Prognostic effects and regulation of Activin A, Maspin, and the androgen receptor in upper urinary tract urotheklial carcinoma. Anticancer research. 2011;31:1713-1720. (SCI; IF=1.725; Oncology 135/184)

26.Lu CC*, Lin SE, Chung KC, Rau KM. Comparison of clinical outcome of single-incision laparoscopic surgery using a simplified access system with conventional laparoscopic surgery for malignant colorectal disease. Colorectal disease. 2012;14:e171-176. (SCI; IF=2.728; Gastroenterology & Hepatology 28/71)

27.Li SH, Rau KM, Lu HI, Wang YM, Tien WY, Liang JL, Lin WC*. Pre-treatment maximal esophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3~4 esophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2012 Mar 30. [Epub ahead of print] (SCI; IF=2.550; Surgery 39/198)

28.Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH*: Analysis of hepatitis B surface antibody titers in B-cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91:1007-1012 (SCI; IF=2.615; Hematology 33/68)

29.Chou WC, Hung YS, Hsu JT*, Chen JS, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC, Sun CF. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology. 2012;95:344-350. (SCI; IF=3.272; Endocrinology and metabolism 46/116)

30.Chen YH#, Li SH#*, Chiu YC, Lu HI, Huang CH, Rau KM, Liu CT. Comparative Study of Esophageal Stent and Feeding Gastrostomy/Jejunostomy for Tracheoesophageal Fistula Caused by Esophageal Squamous Cell Carcinoma. PLoS ONE 2012, 7(8): e42766 (SCI; IF=4.092; Biology 12/84)